Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

KemPharm Inc.

www.kempharm.com

Latest From KemPharm Inc.

Deal Watch: Amgen Outsources Celiac Drug To Provention; Lilly, NextCure Will Co-Discover IO Drugs

Through its Provention collaboration, Amgen partnered with the team that worked on AMG 714 at Celimmune, which the big biotech bought in 2017. Lilly will partner with NextCure to use the latter's FIND-IO platform for immuno-oncology drug discovery.

Deals Business Strategies

Pipeline Watch: Phase III Starts With QPI-1002, Enfortumab Vedotin And ZYN-002

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

 

Pipeline Watch Approvals

Indivior Withdraws 2018 Guidance Due To Competitive Pressures On Suboxone, Sublocade

Suboxone market share has declined with the at-risk launch of Dr. Reddy’s generic competitor, while Indivior awaits a court decision on a requested temporary restraining order against the launch.

Business Strategies Commercial

Not Another Opana: US FDA Panel Rejects PTI’s Remoxy On Intravenous Abuse Concerns

Studies showing oxycodone could be extracted for intravenous use troubled advisory committee members, who worried it would result in the same types of adverse public health effects that led to market withdrawal of Endo’s Opana ER; panelists also were concerned about the ability to partially defeat Remoxy’s extended-release properties by chewing the product.


Advisory Committees Drug Review
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • KemPharm Inc.
  • Senior Management
  • Travis C Mickle, PhD, Pres., CEO & Chmn.
    R. LaDuane Clifton, CFO, Secretary & Treasurer
    Christopher Lauderback, PhD, VP, Manufacturing
    Sven Guenther, PhD, EVP, R&D
    Gordon "Rusty" K Johnson, CBO
    Rene A Braeckman, PhD, VP, Clinical Dev.
  • Contact Info
  • KemPharm Inc.
    Phone: (319) 665-2575
    1180 Celebration Blvd.
    Celebration, FL 34747
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register